BCG-activated killer cells: In-vitro study of specific recognition and killing mechanisms of intravesical immune therapy with BCG;Die BCG-aktivierte killerzelle: Untersuchung spezifischer erkennungs- und tötungsmechanismen zur charakterisierung des wirkprinzips der intravesikalen immuntherapie mit Bacillus Calmette-Guérin

Aktuelle Urologie

Volumn 29, Issue 4, 1998, Pages 175-187

  Bohle A ^a   Durek, Ch ^a   Schafer I ^b   Brandau, S ^b   Ulmer, A J ^b   Flad, H D ^b   Jocham, D ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

Author keywords

BCG; Bladder cancer; Immunotherapy; LAK cells; Mechanisms

Indexed keywords

EID: 0032358192     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1065286     Document Type: Article

References (52)

1. Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K. Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Cancer 1975;75:552-559.
2. Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines: IL 6 and related molecules (IL-1 and TNF). FASEB J. 1990;4:2860-2867.
3. Bichay J, Inch WR. Resistance of multicell spheroids to anthracyclines. Prov Am Ass Cancer Res. 1986;27:384-7.
4. Blay JY, Bertoglio J, Fradelizi D, Chouaib S. Functional interactions of IL-2 and TNF in the differentiation of LGL into LAK effectors. Int J Cancer. 1989;44:598-604.
5. Böhle A, Busemann E, Gerdes J, Ulmer AJ, Flad H-D, Jocham D. In Brown F, Revillard RP, Herausgeber. Developments in biological standardization. Standardization of the immunopharmacology of natural and synthetic immunomodulators. Basel, Karger Verlag; 1992;199.
6. Böhle A, Gerdes J, Ulmer AG, Hofstetter AG, Flad H-D. Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immuocompetent cells of the bladder wall. J Urol. 1990;144:53-58.
7. Böhle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad H-D. Detection of urinary TNF, IL-1, and IL-2 after local BCG immunotherapy for bladder carcinoma. Cytokine 1990;2:175-81.
8. Böhle A, Thanhäuser A, Ulmer AJ, Ernst M, Flad H-D, Jocham D. Dissecting the immunobiological effects of bacillus Calmette-Guérin (BCG) in vitro: Evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol. 1993;150: 1932-7.
9. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Lab Clin Invest. 1968;21:77-89.
10. Braasch H, Wang S, Schäfer I, Ulmer AJ, Flad H-D, Jocham D, Böhle A. Zytotoxizität natürlicher Killerzellen gegen ex vivo isolierte autologe urotheliale Blasentumorzellen bei Patienten mit Blasenkarzinom. Akt Urol. 1995;26 (Suppl.):87-9.
11. Carlsson J, Yuhas JM. In: Acker H, Carlsson J, Durand R, Sutherland RM, Herausgeber. Spheroids in Cancer Research. Recent Results in Cancer Research. Heidelberg, Berlin, New York: Springer Verlag; 1984.
12. Cordell JL, Falini B, Erber WN. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APMP complexes). J Histochem Cytochem. 1984;32:219-29.
13. Durand RE. Chemosensitivity testing in V79 spheroids: drug delivery and cellular microenvironment. J Natl Cancer Inst. 1986;77:247-52.
14. El-Demiry MIM, Smith G, Ritchie AWS, James K, Cumming JA, Hargreave TB, Chisholm GD. Local immune responses after intravesical BCG treatment for carcinoma in situ. Brit J Urol. 1987;60:543-8.
15. Erlichman C, Vidgen C, Wu A. Antineoplastic drug cytotoxicity in a human bladder cancer cell line: implications for intravesical chemotherapy. Urol. Res. 1987;15:13-6.
16. Erlichman C, Vidgen D, Wu A. Cytotoxicity of cisplatin and cis-diammine-1, 1 cylobutane dicarboxylate in MGH-U1 cells grown as monolayers, spheroids and xenografts. J Natl Cancer Inst. 1985;75:499-505.
17. Erlichman C, Wu A. Resistance of MGH-U1 bladder cancer spheroids to vincristine. Anticancer Res. 1992;12:1233-6.
18. Esuvaranathan K, Alexandroff AB, McIntyre M, Jackson AM, Prescott S, Chisholm GD, James K. Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J Urol. 1995;154:572-5.
19. Fellows GJ, Parmar MK, Grigor KM, Hall RR, Heal MR, Wallace DM. Marker tumor response to Evans and Pasteur bacille Calmette-Guérin in multiple recurrent pTa/pT1 bladder tumors: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br J Urol. 1994:l73:639-44.
20. Hawkyard SJ, Jackson AM, Hawkins RA, James K, Smyth JF, Chisholm GD. Expression of interferon-γ receptors on bladder cancer cells: does it correlate with biological response? Urol Res. 1992;20:229-32.
21. Holtfreter J. A study of the mechanisms of gastrulation. J Exp Zool. 1994;106:197-204.
22. Jääskeläinen J, Kalliomäki P, Paetau A, Timonen T. Effect of LAK cells against three-dimensional tumor tissue. In vitro study using multi-cellular human glioma spheroids as targets. J Immunol. 1989;142:1036-45.
23. Kataoka T, Shinohara N, Takayama H, Takaku K, Kondo S, Yonehara S, Nagai K. Concanmycin A, a powerful tool for characterisation and estimation of contribution of perforin- and FAS-based lytic pathways in cell-mediated cytotoxicity. J Immunol. 1996;156: 3678-86.
24. Kataoka T, Takaku K, Megae J, Shinohara N, Takayama H, Kondo S, Nagai K. Acidification is essential for maintaining the structure and function of lytic granules of CTL. J Immunol. 1994;153:3938-47.
25. Kaufman DS, Schoon RA, Leibson PJ. MHC class I expression on tumor targets inhibitis NK cell-mediated cytotoxicity without interfering with target recognition. J Immunol. 1993;150:1429-36.
26. Kelley DR, Haaff EO, Becich MJ, Lage J, Bauer WC, Dresner SM, Catalona WJ, Ratliff TL. Prognostic value of PPD skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guérin. J Urol. 1986;135:268-71.
27. Knüchel R, Hofstädter F, Sutherland RM, Keng PC. Proliferation-associated antigens PCNA and Ki-67 in two- and three-dimensional experimental systems of human sqamous epithelial carcinomas. Verh Dtsch Ges Pathol. 1990;74:275-8.
28. Lee RS, Schlumberger M, Caillou B, Pages F, Fridman WH, Tartour E. Phenotypic and functional characterisation of tumor infiltrating lymphocytes derived from thyroid tumors. Eur J Cancer. 1996;32:1233-9.
29. Leibold WB, Bridge S. 75 Se-release: a short and long-term assay system for cellular cytotoxicity. Z. Immun Forsch. 1979;155:287-311.
30. Masters JRW, Hepburn PJ, Walker L, Highman WJ, Trejdosiewicz LK, Povey S, Parkar M, Hill BT, Riddle PR, Franks LM. Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines. Cancer Res. 1986;46:3630-6.
31. Moretta L, Ciccone E, Mingari MC, Biassone A, Moretta A. Human natural killer cells: origin, clonality, specificity and receptors. Adv Immunol. 1994;55:341-80.
32. Moscona A. Rotation mediated histogenic aggregation of dissociated cells. A qualifiable approach to cell interaction in vitro. Exp Cell Res. 1961;22:225-31.
33. Nederman T, Carlsson L, Malmquist M. Penetration of substances into tumor tissue - a methodological study on cellular spheroids. In Vitro. 1981;17:290-8.
34. Perussia B. Lymphokine activated killer cells, natural killer cells and cytokines. Curr Opin Immunol. 1991;3:49-55.
35. Podack ER. In Griffiths JM, Tschopp J, Herausgeber. Pathway for cytolysis. Berlin: Springer; 1995.
36. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol. 1990;144:1248-51.
37. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol. 1992;147:1636-42.
38. Sacks PG, Taylor DL, Racz T, Vasey T, Oke V, Schantz SP. A multicellular tumor spheroid model of cellular immunity against head and neck cancer. Cancer Immunol Immunother. 1990;32:195-200.
39. Sander B, Damm O, Gustafsson B, Andersson U, Hakansson L. Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical Bacillus Calmette-Guérin. J Urol. 1996;156:536-41.
40. Shapiro A, Ratliff TL, Oakley DM, Catalona WJ. Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guérin and its correlation with bacillus Calmette-Guérin viability and natural killer cell activity. Cancer Res. 1983;43:1611-15.
41. Shemtov M, Li-Wei Chen D, Kong L, Shu WP, Sassaroli M, Droller MJ, Liu BCS. LAK cell mediated apoptosis of human bladder cancer cells involves a pH-dependent endonuclease system in the cancer cell: possible mechanism of BCG therapy. J Urol. 1995;154:269-74.
42. Sutherland RM, Buchegger F, Schreyer M, Mach JP. Penetration and binding of radiolabelled anti-CEA monoclonal antibodies and their F(ab′) and Fab fragments in human colon multicellular tumor spheroids. Cancer Res. 1987;47:1627-33.
43. Sutherland RM, Eddy HA, Bareham B, Reich K, Vanantwerp D. Resistance to adriamycin in multicellular spheroids. J Radiat Oncol Biol Phys. 1979;5:1255-30.
44. Thanhäuser A, Böhle A, Flad H-D, Ernst M, Mattern T, Ulmer AJ. Induction of bacillus Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Cancer Immunol Immunother. 1993;37:105-11.
45. Thanhäuser A, Böhle A, Schneider B, Reiling N, Flad H-D, Ulmer AJ. Lymphokine-activated killer (LAK) and bacillus Calmette-Guérin-activated killer (BAK) cells: two ways of activation of cytotoxic effector cells against baldder tumor cells in vitro. Eur J Cell Biol. 1994;63(Suppl.40):74.
46. Thanhäuser A, Böhle A, Schneider B, Reiling N, Mattern T, Ernst M, Flad H-D, Ulmer AJ. The induction of bacillus Calmette-Guérin-activated killer cells requires the presence of monocyles/macrophages and T-helper type 1 cells. Cancer Immunol Immunother. 1995;40:103-8.
47. Thanhäuser A, Ulmer AJ, Böhle A, Mattern T, Ernst M, Flad H-D. Induction of Lymphokine- (LAK) and Bacillus Calmette-Guérin-acitivated Killer (BAK) cells against bladder tumor cell lines. Ann Hematol. 1993;66(Supp II):A108.
48. + myelin reactive T cells lyses target cells expressing CD56 (NCAM). J Immunol. 1996;167:679-88.
49. Walker MC, Masters JRW, Parris CN, Hepburn PJ, English PJ. Intravesical chemotherapy: in vitro studies on the relationship between dose and cytotoxicity. Urol Res. 1986;14:137-40.
50. Wang M-H, Flad H-D, Böhle A, Chen YQ, Ulmer AJ. Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines. Immunol letters. 1991;27:191-8.
51. West GW, Weichselbaum R, Little JB. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res. 1980;40:3635-68.
52. Xiao L, Eneroth PHE, Qureshi GA. Nitric oxide synthase pathway may mediate human NK cell cytotoxicity. Scand J Immunol. 1995;42:505-11.